Min Jung Chang

MODEL-informed nivolumab less frequent dosing using virtual patients with solid tumors

Less frequent nivolumab dosing has been assessed for more efficient dosing, but there is no conclusive evidence. In this research, we suggested an appropriate model-informed drug dosing using virtual patients collected from the results of multiple clinical studies to provide a ra...

Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer

CT-P16 (Vegzelma ® ) is a bevacizumab biosimilar approved for indications including non-squamous non-small cell lung cancer. We developed an integrated population pharmacokinetic model pooling data from two phase I studies in healthy subjects and one phase III study in patients w...